An Update on Therapies for Proliferative Lupus Nephritis: How Certain Can We Be About the Evidence?

Overview

Journal Am J Kidney Dis

Specialty Nephrology

Date 2018 Oct 23

PMID 30343733

Citations 5

Authors

Andrew S Bomback

Affiliations

Soon will be listed here.

Citing Articles

Machine learning models predicts risk of proliferative lupus nephritis.

Yang P, Liu Z, Lu F, Sha Y, Li P, Zheng Q Front Immunol. 2024; 15:1413569.

PMID: 38919623 PMC: 11196753. DOI: 10.3389/fimmu.2024.1413569.

Searching for a prognostic index in lupus nephritis.

Rodriguez-Almaraz E, Gutierrez-Solis E, Rabadan E, Rodriguez P, Alonso M, Carmona L Eur J Med Res. 2023; 28(1):19.

PMID: 36631838 PMC: 9832788. DOI: 10.1186/s40001-022-00946-y.

Elevated soluble CD163 predicts renal function deterioration in lupus nephritis: a cohort study in Eastern China.

Yang G, Guo N, Yin J, Wu J J Int Med Res. 2021; 49(11):3000605211049963.

PMID: 34755559 PMC: 8586176. DOI: 10.1177/03000605211049963.

Analysis of clinical and laboratory characteristics and pathology of lupus nephritis-based on 710 renal biopsies in China.

Song K, Liu X, Liu J, Yin Z, Chen P, Cai G Clin Rheumatol. 2020; 39(11):3353-3363.

PMID: 32435895 DOI: 10.1007/s10067-020-05115-2.

Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages.

Zhang T, Li H, Vanarsa K, Gidley G, Mok C, Petri M Front Immunol. 2020; 11:671.

PMID: 32351512 PMC: 7174755. DOI: 10.3389/fimmu.2020.00671.

References

Appel G, Contreras G, Dooley M, Ginzler E, Isenberg D, Jayne D . Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20(5):1103-12. PMC: 2678035. DOI: 10.1681/ASN.2008101028. View

Ward M . Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol. 2008; 36(1):63-7. PMC: 2679678. DOI: 10.3899/jrheum.080625. View

Ward M . Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med. 2000; 160(20):3136-40. DOI: 10.1001/archinte.160.20.3136. View

Bao H, Liu Z, Xie H, Hu W, Zhang H, Li L . Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008; 19(10):2001-10. PMC: 2551567. DOI: 10.1681/ASN.2007121272. View

Ginzler E, Dooley M, Aranow C, Kim M, Buyon J, Merrill J . Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353(21):2219-28. DOI: 10.1056/NEJMoa043731. View

Tunnicliffe D, Palmer S, Henderson L, Masson P, Craig J, Tong A . Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018; 6:CD002922. PMC: 6513226. DOI: 10.1002/14651858.CD002922.pub4. View

Flanc R, Roberts M, Strippoli G, Chadban S, Kerr P, Atkins R . Treatment for lupus nephritis. Cochrane Database Syst Rev. 2004; (1):CD002922. DOI: 10.1002/14651858.CD002922.pub2. View

Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z . Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2014; 162(1):18-26. DOI: 10.7326/M14-1030. View

Rovin B, Furie R, Latinis K, Looney R, Fervenza F, Sanchez-Guerrero J . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64(4):1215-26. DOI: 10.1002/art.34359. View

10.

Henderson L, Masson P, Craig J, Flanc R, Roberts M, Strippoli G . Treatment for lupus nephritis. Cochrane Database Syst Rev. 2012; 12:CD002922. DOI: 10.1002/14651858.CD002922.pub3. View

11.

Bomback A, Appel G . Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010; 21(12):2028-35. DOI: 10.1681/ASN.2010050472. View

12.

Palmer S, Tunnicliffe D, Singh-Grewal D, Mavridis D, Tonelli M, Johnson D . Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2017; 70(3):324-336. DOI: 10.1053/j.ajkd.2016.12.008. View

13.

Tunnicliffe D, Palmer S . Immunosuppressive Treatment for Proliferative Lupus Nephritis: Summary of a Cochrane Review. Am J Kidney Dis. 2018; 72(5):756-757. DOI: 10.1053/j.ajkd.2018.07.008. View

14.

Dooley M, Jayne D, Ginzler E, Isenberg D, Olsen N, Wofsy D . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365(20):1886-95. DOI: 10.1056/NEJMoa1014460. View

15.

Alvarado A, Malvar A, Lococo B, Alberton V, Toniolo F, Nagaraja H . The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus. 2014; 23(8):840-7. DOI: 10.1177/0961203313518625. View

16.

Furie R, Nicholls K, Cheng T, Houssiau F, Burgos-Vargas R, Chen S . Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014; 66(2):379-89. DOI: 10.1002/art.38260. View